Jason Aryeh, Director at Orchestra BioMed Holdings, Inc. (OBIO), bought 8,971 shares at $3.90 ($35K) on 2026-05-15, disclosed to the SEC on 2026-05-19.
Director Jason Aryeh purchased $34,987 of OBIO stock at $3.90, marking the largest purchase of his career. This action follows a cluster of two other insider buys in the last 30 days, suggesting confidence despite recent revenue misses.
OBIO is down 11.94% over the last 30 days and currently trades 25.88% below its 52-week high of $5.424.
Catalysts include the recent cluster of two insider buys in the last 30 days, TD Cowen's Buy rating and $15 price target initiated on December 31, 2025, and the Q4 earnings beat of +168.87% EPS and +3,813.54% revenue on March 12, 2026.
Risks include the Q1 revenue miss of -94.27% on May 12, 2026, and Barclays' reduction of the price target from $12 to $11 on November 29, 2025.
Something here stands out, but not much.
| Filing → |
| LGND | SELL | 2025-09-24 | $3.4M | — | Filing → |
| OBIO | BUY | 2025-09-19 | $2K | — | Filing → |
| LGND | BUY | 2019-09-04 | $131K | — | Filing → |